OKYO Pharma Limited (OKYO)
Nasdaq: OKYO · Biological Products, (No Diagnostic Substances) · London, GB · filing with the SEC since 2021
Who runs OKYO Pharma Limited
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Dempsey Robert John
CHIEF EXECUTIVE OFFICER. First filing May 2026, latest Aug 7, 2026, 1 filing in all.
Officers reporting now
6
of 9 people with a filing in the last fifteen months
Directors reporting now
3
10 people on the record since 2022
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Dempsey Robert John | CHIEF EXECUTIVE OFFICER | May 2026 | Aug 7, 2026 | none |
| Cerrone Gabriele M | Executive Chairman | May 2022 | Aug 7, 2026 | none |
| Jacob Gary S | CHIEF DEVELOPMENT OFFICER | May 2022 | Aug 7, 2026 | none |
| Mantelli Flavio | CHIEF MEDICAL OFFICER | Jun 2026 | Aug 7, 2026 | none |
| Patil Rajkumar V. | Chief Scientific Officer | Jul 2026 | Aug 7, 2026 | none |
| Shah Keeren Rameshchandra | Chief Financial Officer | May 2026 | Jun 10, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Brancaccio John P | director | May 2022 | Aug 7, 2026 | none |
| Denoyer Bernard | director | May 2022 | Jun 10, 2026 | none |
| Simon Willy Jules | director | May 2022 | Jun 10, 2026 | none |
Earlier names on the record1, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.